Director D Jeffrey Keyser buys 48.5K shares of LTRN at $2.06; stock up 34.3% in 30 days but down 45.5% from 52-week high
Director D Jeffrey Keyser's $100.0K purchase of 48.5K shares at $2.06 represents a meaningful commitment during a period of stock volatility—the company trades 45.5% below its 52-week high of $5.74 yet has rallied +34.3% over the past 30 days. This insider buy occurs while Lantern Pharma faces structural unprofitability with net income of $-4,177,423.00 against a modest market cap of $35.4M, suggesting the director sees value despite current losses. The timing signal is mixed: the 30-day momentum is positive, but the persistent discount to recent highs and negative fundamentals warrant scrutiny as to whether this reflects conviction in turnaround prospects or a bottom-fishing move at cyclical lows.